Therefore, if an anticancer drug selectively inhibits the expression of survivin, XIAP, Mcl-1 and cIAP2 in a p53 pathway-independent manner, this drug would show high efficacy to selectively induce cancer cell killing regardless of p53 status. Here, BIRC5 is linked to cancer.